Gengos Andrew — SEC Form 4 filings
SEC reporting owner CIK 1563623. 11 Form 4 filings on record with FilingPulse; latest filed 2026-07-17.
Transaction summary — filings shown
Covers all 11 filings on record, filed 2024-02-16 to 2026-07-17. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 5 legs across 2 filings — 25,000 shares, $96,366 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 2 legs across 2 filings — 2,480 shares, $4,235 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 14.
- Largest priced transaction: purchase of 5,000 shares @ $3.95 ($19,732) in Terns Pharmaceuticals, Inc., filed 2025-06-16.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Terns Pharmaceuticals, Inc. (TERN) | Chief Financial Officer | 5 | 5 legs · 25,000 sh · $96,366 | — | 7 |
| Athira Pharma, Inc. (ATHA) | CFO and Chief Business Officer | 3 | — | 2 legs · 2,480 sh · $4,235 | 4 |
| Turn Therapeutics Inc. (TTRX) | Director | 2 | — | — | 2 |
| Immuneering Corp (IMRX) | Chief Financial Officer | 1 | — | — | 1 |
Form 4 filings — Gengos Andrew
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-17 | 4 | Immuneering Corp (IMRX) | Grant/award (A): 650,000 (derivative) @ $0 | EDGAR |
| 2026-06-08 | 4 | Turn Therapeutics Inc. (TTRX) | Grant/award (A): 95,000 (derivative) @ $0 | EDGAR |
| 2026-05-05 | 4 | Terns Pharmaceuticals, Inc. (TERN) | Code (U): 40,503 @ $53 · Disposition to issuer (D): 68,750 @ $53 · Disposition to issuer (D): 750,000 (derivative) · Disposition to issuer (D): 137,500 (derivative) | EDGAR |
| 2026-01-16 | 4 | Terns Pharmaceuticals, Inc. (TERN) | Grant/award (A): 68,750 @ $0 · Grant/award (A): 137,500 (derivative) @ $0 | EDGAR |
| 2025-10-10 | 4 | Turn Therapeutics Inc. (TTRX) | Grant/award (A): 10,000 @ $0 | EDGAR |
| 2025-06-30 | 4 | Terns Pharmaceuticals, Inc. (TERN) | Purchase (P): 5,000 @ $3.93 · Purchase (P): 5,000 @ $3.93 | EDGAR |
| 2025-06-16 | 4 | Terns Pharmaceuticals, Inc. (TERN) | Purchase (P): 5,000 @ $3.75 · Purchase (P): 5,000 @ $3.72 · Purchase (P): 5,000 @ $3.95 | EDGAR |
| 2025-02-25 | 4 | Terns Pharmaceuticals, Inc. (TERN) | Grant/award (A): 750,000 (derivative) @ $0 | EDGAR |
| 2024-09-05 | 4 | Athira Pharma, Inc. (ATHA) | Grant/award (A): 10,000 @ $1.34 · Grant/award (A): 5,000 @ $0 · Sale (S): 1,272 @ $0.57 | EDGAR |
| 2024-02-16 | 4/A | Athira Pharma, Inc. (ATHA) | Grant/award (A): 5,000 @ $0 · Sale (S): 1,208 @ $2.91 | EDGAR |
| 2024-02-16 | 4 | Athira Pharma, Inc. (ATHA) | Grant/award (A): 280,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1563623 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →